2006 JASN IMPACT FACTOR 7.371	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007050582v1 19/4/771    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Parving, H.-H. Articles by Brenner, B. M. PubMed PubMed Citation Articles by Parving, H.-H. Articles by Brenner, B. M.

ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy

Hans-Henrik Parving^*, Dick de Zeeuw, Mark E. Cooper, Giuseppe Remuzzi, Nancy Liu^||, Jared Lunceford^||, Shahnaz Shahinfar^||, Peggy H. Wong^||, Paulette A. Lyle^||, Peter Rossing^¶ and Barry M. Brenner^**

^* Department of Medical Endocrinology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark; Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Danielle Alberti Memorial Centre for Diabetes Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia; Mario Negri Laboratories and Clinical Research Center, Ranica, Italy; ^|| Merck Research Laboratories, West Point, Pennsylvania; ^¶ Steno Diabetes Center, Gentofte, Denmark; and ^** Renal Division, Brigham and Women's Hospital, Boston, Massachusetts

Correspondence: Prof. Hans-Henrik Parving, Department of Medical Endocrinology, Department 2132, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark. Phone: 45 22 17 8160; Fax: 45 44 43 8232; E-mail: hhparving{at}dadlnet.dk

Received for publication May 18, 2007. Accepted for publication October 17, 2007.

Losartan treatment reduced renal outcomes in proteinuric patients with type 2 diabetes in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. It is unknown whether an insertion (I)/deletion (D) polymorphism in the angiotensin I-converting enzyme (ACE) gene predicts renal outcomes and death and influences the effect of losartan in these patients. Pharmacogenetic analyses were performed comparing losartan with placebo administered with conventional blood pressure-lowering therapy in 1435 (95%) of the 1513 RENAAL study patients. The primary endpoint was the composite of doubling of baseline serum creatinine concentration, end-stage renal disease (ESRD) or death. Cox regression models were stratified on baseline proteinuria and included treatment, geographic region, ACE/ID genotype, and treatment x genotype interaction. Within the placebo group, subjects with the ID or DD genotype were more likely than those with the II genotype to reach the composite endpoint (by 17.5% and 38.1%, respectively, P = 0.029) or its individual components. Within the losartan group, genotype did not correlate with reaching the composite endpoint. Compared with placebo, however, losartan reduced the risk of reaching the composite endpoint by 5.8% (95% confidence interval, –23.3, 28.0), 17.6% (3.8, 29.4), and 27.9% (7.0, 44.1) among those with the II, ID, and DD genotypes, respectively. Similar trends were demonstrated for the individual endpoints. In conclusion, proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavorable renal prognosis, which can be mitigated and even improved by losartan.

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673